Sanghvi Neil K, Tracy Cynthia M
Department of Medicine, George Washington University Hospital, Washington, DC.
Pacing Clin Electrophysiol. 2007 Jun;30(6):799-803. doi: 10.1111/j.1540-8159.2007.00753.x.
The prevalence of hypertrophic cardiomyopathy is estimated at 1:500 in the general population. Of these patients, approximately 1% develops midcavitary obstruction and subsequent apical aneurysm. We present a brief review of the literature on apical hypertrophic cardiomyopathy (HCM) using a rare case-based example. The etiology for apical aneurysm development is unclear but is thought to extend from apical fibrosis and necrosis secondary to subendocardial ischemia. The lifetime risk of cardiovascular death in patients with HCM is 2%. However, the risk may be higher in patients with apical aneurysms. Definitive therapy involves implantation of an automatic implantable cardioverter defibrillator, since medical therapy has variable success.
肥厚型心肌病在普通人群中的患病率估计为1:500。在这些患者中,约1%会出现心腔中部梗阻及随后的心尖部室壁瘤。我们以一个罕见的病例为例,对有关心尖肥厚型心肌病(HCM)的文献进行简要综述。心尖部室壁瘤形成的病因尚不清楚,但被认为是由心内膜下缺血继发的心尖纤维化和坏死发展而来。肥厚型心肌病患者心血管死亡的终生风险为2%。然而,有心尖部室壁瘤的患者风险可能更高。由于药物治疗效果不一,确切的治疗方法是植入自动植入式心脏复律除颤器。